11
total announcements
NATHBIOGEN.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹266 Cr
P/E (TTM)
7.6
EPS (TTM)
₹18.43
52W Low
₹126.15
52W High
₹204.00
Dividend Yield
1.47%
Beta
0.85
Price / Book
0.5
Debt / Equity
20.4
Revenue (TTM)
₹490 Cr
Gross Margin
53.76%
Operating Margin
10.40%
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has held its 33rd Annual General Meeting (AGM) on September 24, 2026, via video conferencing. The meeting passed various resolutions, including the adoption of the audited standalone and consolidated balance sheet, declaration of a final dividend, and re-appointment of directors.
Nath Bio-Genes (India) Limited
NSE-listed Nath Bio-Genes (India) Limited has received a clarification request from the exchange regarding its financial results for the quarter ended June 30, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 11-Sep-2026.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026, to consider and adopt the Audited Balance Sheet, Statement of Profit & Loss, and to declare a final Dividend of ₹ 2 per equity shares.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has received a communication from SEBI to appoint a forensic auditor to conduct an audit of the company's books of account and records for the financial years 2020-21 to 2025-26.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the Exchange about General Updates, including the presentation of unaudited financial results for the period ended 30th June 2026, with a 15% growth in revenue and a 12% growth in PAT.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 3265.68 lakhs and a basic earnings per share of Rs. 17.18.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has submitted a compliance certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities up to 30th June 2026.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from July 1, 2026, to 48 hours after the declaration of Unaudited Financial Results for the quarter ending June 30, 2026.
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited has informed the exchanges about the submission of its annual disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing, made by the company's promoters for the financial year ended March 31, 2026, pertains to details of any shares encumbered (e.g., pledged). While the specific details of encumbrances are not provided in this announcement, it signifies the company's compliance with regulatory requirements concerning promoter shareholdings. Investors often monitor such disclosures for insights into promoter commitment and financial standing.